Here are what the editors at HealthDay consider to be the most important developments in Pulmonology for January 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
FDA Approves First Generic Version of Advair for Asthma, COPD
THURSDAY, Jan. 31, 2019 (HealthDay News) — The first generic form of the Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler has been approved by the U.S. Food and Drug Administration.
E-Cigarettes More Effective for Smoking Cessation
THURSDAY, Jan. 31, 2019 (HealthDay News) — Electronic cigarettes are more effective for smoking cessation than nicotine replacement therapy, according to a study published online Jan. 30 in the New England Journal of Medicine.
No Asthma Benefit Seen With n3PUFA in Overweight Teens
WEDNESDAY, Jan. 30, 2019 (HealthDay News) — Omega-3 fatty acid (n3PUFA) supplements do not appear to improve asthma control in teens and young adults who are overweight or obese, according to a study published online Jan. 25 in the Annals of the American Thoracic Society.
Lean Body Mass in Childhood Linked to Lung Function at 15
FRIDAY, Jan. 25, 2019 (HealthDay News) — Higher lean body mass during childhood and adolescence is associated with higher lung function at age 15 years for both sexes, according to a study published online Jan. 11 in the American Journal of Respiratory and Critical Care Medicine.
Report IDs Areas Lacking Good Practice in Health Tech Assessment
FRIDAY, Jan. 25, 2019 (HealthDay News) — In a report published in the January issue of Value in Health, an ISPOR–The Professional Society for Health Economics and Outcomes Research working group indicates the lack of good practices in three areas of health technology assessment (HTA).
CDC: Proportion of Increased-Risk Deceased Organ Donors on Rise
THURSDAY, Jan. 24, 2019 (HealthDay News) — Among deceased organ donors, there has been an increase in the proportion at increased risk for transmitting hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV to recipients, according to research published in the Jan. 25 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Plasma Marker Predicts Allograft Failure in Lung Transplant
THURSDAY, Jan. 24, 2019 (HealthDay News) — Donor-derived cell-free DNA (ddcfDNA) is a potential biomarker that can predict allograft failure after lung transplantation, according to a study published online Jan. 23 in EBioMedicine.